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Abstract
Background: A common feature of neuroblastoma tumours are partial deletions of the short arm
of chromosome 1 (1p-deletions). This is indicative of a neuroblastoma tumour suppressor gene
being located in the region. Several groups including our have been studying candidate
neuroblastoma genes in the region, but no gene/genes have yet been found that fulfil the criteria
for being a neuroblastoma tumour suppressor. Since frequent mutations have not been detected,
we have now analyzed the expression and promoter CpG island methylation status of the genes
UBE4B, KIF1B, PGD, APITD1, DFFA and PEX14 in the 1p36.22 region in order to find an explanation
for a possible down-regulation of this region.
Results: The current study shows that gene transcripts in high stage neuroblastoma tumours are
significantly down-regulated compared to those in low stage tumours in the 1p36.22 region. CpG
island methylation does not seem to be the mechanism of down-regulation for most of the genes
tested, since no methylation was detected in the fragments analyzed. One exception is the CpG
island of APITD1. Methylation of this gene is also seen in blood from control individuals and is
therefore not believed to participate in tumour development.
Conclusion: The genes UBE4B, KIF1B, PGD, APITD1, DFFA and PEX14 are down-regulated in high
stage NB tumours, a feature that can not be explained by CpG island methylation.
Background
Neuroblastoma (NB) is the most common paediatric
solid tumour, responsible for 15% of cancer deaths of
childhood. It is a tumour of the postganglionic sympa-
thetic nervous system that develops from immature or
dedifferentiated neural crest-derived cells [1]. The distal
part of chromosome 1p shows loss of heterozygosity
(LOH) in 20–40% of NB tumours and has therefore been
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We and others have previously analyzed the chromo-
somal region 1p36.2-3 [2-12] and we have recently
focused on the gene region involving the genes: UBE4B-
KIF1B-PGD-APITD1-CORT-DFFA-PEX14. These genes
have been analyzed for mutations and a few have been
found in rare tumours [13-17].
In search of tumour suppressor genes, the focus has in the
last years moved towards epigenetics and methylation of
promoter regions. Methylation of cytosines in CpG-dinu-
cleotides is a common modification in mammalian
genomes. Methylated cytosines are more susceptible to
deamination, which have lead to an erosion of the
number of CpG-dinucleotides. The vast majority of CpGs
resides within repetitive elements and is methylated.
There are also stretches of DNA rich in CpG that are gene
associated, i.e. CpG islands, which are normally unmeth-
ylated [18]. Methylation is generally associated with
repression of transcription. Gene regulation by methyla-
tion includes tissue-specific regulation during develop-
ment and processes as X-chromosome inactivation and
genomic imprinting, reviewed by Herman and co-work-
ers. [19]. Cancer is associated with a genome-wide
hypomethylation and a more gene-specific hypermethyl-
ation. Hypermethylation of CpG islands has been shown
to be a common mechanism for the inactivation of
tumour suppressor genes and is found in a wide range of
tumour types [20-23]. According to the Knudson two-hit
hypothesis, two successive mutations are required to inac-
tivate a tumour suppressor gene and turn a normal cell
into a malignant one. Inactivation could be due to dele-
tions or mutations. Epigenetic events, such as hypermeth-
ylation of promoter-associated CpG islands have come in
focus during the last decade as a route to inactivation [19].
The most common way to analyze methylation status is
based on bisulphite modification of DNA [24]. In this
reaction, unmethylated cytosines are deaminated to
uracil, while methylated cytosines remain unconverted.
The region of interest can be amplified using non-discrim-
inating primers, amplifying both methylated and
unmethylated templates in one reaction, or with methyl-
ation-specific PCR (MSP) in which methylated and
unmethylated templates are amplified in separate reac-
tions [25].
Some genes have been analyzed in NB tumours focusing
on methylation status. For example, CASP8, on 2q33, was
one of the first genes found to be methylated in neurob-
lastoma, with a frequency of about 40 % in primary NB
tumours [26]. On 3p21.3, RASSF1A and BLU have been
shown to be frequently methylated [27-29]. In a study by
van Noesel and co-workers, 34 genes in 12 different chro-
mosomal regions were analyzed in neuroblastoma cell
lines [30]. A total of six genes that were methylated in at
least three of the 22 cell lines were found. CASP8, as
already known, was one of these genes, also FLIP at 2q33
was methylated as well as four genes in the chromosome
region 8p21; DR4, DR5, DCR1 and DCR2. Genes on 1p36
were also included in this study, none of which were
found to be methylated. No genes in the NB tumour sup-
pressor candidate region on 1p36.22 were included. Ala-
minos and co-workers have in a study screened 45 genes
in NB cell lines [31]. 34 genes were found to be methyl-
ated in at least one of the ten cell lines. The analysis also
demonstrated that the percentage of methylated genes
was higher in cell lines with MYCN-amplification than in
those without. UBE4B, located in 1p36.22, was included
in this study and found to be unmethylated.
The genes in the 1p36 consensus deleted region are all,
except for CORT, associated with a CpG island in their
respective promoter regions. The fact that this region is
deleted in a subset of NB tumours and that frequent muta-
tions are not found, makes it a possible candidate region
for hypermethylation of genes. In the current study, we
wanted to analyze the expression pattern of these genes in
the 1p36.22 region using TaqMan technology and the
methylation status of promoter regions associated with




GUSB was selected as an endogenous control for real-time
PCR quantification, and further used as an internal refer-
ence for normalization. Real time-PCR studies of all the
genes in the region on cDNA-samples showed a signifi-
cant reduction of mRNA levels in high stage NB tumours
compared to low stage tumour mRNA levels, ranging
from 49% for PEX14 to 79% for APITD1 (Table 4) [16].
The average expression in NB cell lines compared to pri-
mary tumours varied between the different genes in the
region. Cell lines showed a higher expression of APITD1
and DFFA compared to primary tumours. Lower expres-
sion in cell lines was seen in KIF1B and equal levels of cell
lines and stage 2 primary tumours in UBE4B, PGD and
PEX14 (Table 4; Fig. 1). The 1p-deleted cell line SK-N-AS
generally showed lower expression of the genes in the
region compared to the other NB cell lines tested (Fig. 1).
Methylation analysis
The analyzed fragments of the genes UBE4B, KIF1B, PGD,
DFFA and PEX14 were not methylated in the panel of NB
primary tumours and cell lines. For APITD1, the region -
393 to -222 relative to initiation codon showed methyla-
tion. This region was therefore amplified and cloned with
a T/A cloning kit in order to give a value of the percentagePage 2 of 9
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16 CpG sites and these sites show various degree of meth-
ylation, in different clones as well as in different samples.
Methylation of cytosine in front of guanine is concen-
trated to the beginning of this "methylated region"; the
three first cytosine bases showing the highest degree of
methylated clones (Fig 3). No methylation was seen up-
stream of -393 in the fragments analyzed. At some CpG
sites in the region, methylation was never detected. Only
one sample had no clones with methylation for any of the
sites; the stage 2 tumour 20S9. Blood from control indi-
viduals also showed various degree of methylation at
these sites. The cell lines did not show methylation down-
stream of CpG -212 in the analyzed fragments, clones
from tumours were not methylated down-stream of CpG
-311. Healthy controls showed a smaller region of meth-
ylation, no methylated clones were detected down-stream
of CpG -280.
Discussion
Deletion of parts of chromosome 1p is a common feature
of neuroblastoma tumours. We have previously narrowed
down the shortest region of overlap of deletions (SRO) to
25 cM in our tumour material [6,7]. By including a germ
cell tumour with 1p deletion we could confine the SRO to
5 cM [11]. This SRO was further confirmed when a cell
line with a homozygous deletion of 500 kb was found
within this region [32]. We have previously screened the
500 kb region for mutations and only rare have been
detected. The aim of this study was to investigate the
expression of the genes in the region and to correlate this
with the methylation status. TaqMan expression data
showed a clear down-regulation in gene expression of
genes in the region tested when comparing high stage NB
tumours (stage 3 and 4) and low stage tumours (stage 2).
This down-regulation was seen regardless if the high stage
tumour was 1p-deleted or not (Fig. 1). This finding further
supports that this region might be involved in NB devel-
opment and progression. We can speculate about some
central mechanism for the expression of the genes in the
entire region that is affected in tumours with poor prog-
nosis, either due to the deletion of one allele and/or by
some other mechanism. An attractive explanation for this
would be methylation of CpG islands that can lead to
inactivation of the respective gene. This does not seem to
be the case though, since none of the genes, APITD1
excepted, showed methylation. Furthermore, DNA from
healthy controls is also methylated in the same region of
the APITD1 gene, making methylation a less likely expla-
nation for the difference in APITD1 gene expression
between advanced and favourable primary NB tumours.
CpG methylation is not the only possible explanation for
the down-regulation in gene expression shown in high
stage tumours. Analysis of chromatin modifications could
be the next step in a further analysis of this region, in
search of a mechanism that could lead to down-regulation
of the genes. Deficiencies in transcription factors and
upstream elements could also account for the decrease in
gene transcripts. Another possibility is that the variations
are due to differences in the treatment of the tumours
before and after surgery. Radiation and chemotherapy
could probably have a vast affect on the expression pat-
terns of a substantial amount of genes in the tumour cell.
It is however unlikely that all the genes in the analyzed
region would be affected by the treatment alone, rather
this might explain the differences in the level of down-reg-
ulation between different genes.
The difference in expression between NB cell lines and pri-
mary NB could be explained by the difference in cell envi-
ronment between cells in culture and in vivo. In primary
tumours, there are always some non-NB cells in the RNA
preparations that might affect the gene expression results.
On the other hand, genetic events happen to the cells
when they get immortalized in cell culture, some genes
tend to be down-regulated and others up-regulated. We
can also speculate that some of these genes, for example
APITD1, might even be so crucial that only cells with
expression of this gene are capable of surviving in culture.
Table 4: Average relative gene expression (gene/GUSB).
Gene Average relative expression in 
NB cell lines
Average relative expression in 
low stage NB
Average relative expression in 
high stage NB
% less expression in high stage 
NB compared to low stage NB
UBE4B 1.1 1.2 0.33 73%
KIF1B 0.51 3.6 0.99 72%
PGD 0.95 1.1 0.38 65%
APITD1 1.3 0.35 0.075 79%
DFFA 1.5 1.2 0.51 57%
PEX14 1.1 1.9 0.96 49%
Data analysed by TaqMan, and grouped in neuroblastoma cell lines, low stage primary tumours and high stage NB primary tumours.Page 3 of 9
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Molecular Cancer 2005, 4:10 http://www.molecular-cancer.com/content/4/1/10Expression studies using the TaqMan-technique for detecting mRNA in NB cell lines and primary tumoursFigure 1
Expression studies using the TaqMan-technique for detecting mRNA in NB cell lines and primary tumours. The 
results are grouped into three groups indicated at the top; also the 1p-deletion status for each sample is indicated at the top. 
The genes tested are indicated to the left. The Y-axis indicates relative expression level compared to the housekeeping gene 
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In conclusion, in our aim to find a mechanism that could
inactivate the genes in the candidate gene region we ana-
lyzed the expression status and the methylation profile of
six genes. The techniques used were TaqMan real-time-RT-
PCR technology and bisulphite DNA sequencing. Of the
genes analyzed all were down-regulated in high staged NB
tumours as compared to low stage tumours. Promoter
methylation was not detected in the genes analyzed,
except for the CpG island of APITD1. This methylation
does not seem to be tumour specific, since methylation
was also detected in healthy blood controls. Hence, the six
genes UBE4B, KIF1B, PGD, APITD1, DFFA and PEX14 are
down-regulated in high stage NB tumours, a feature that
can not be explained by methylation, rather by a mecha-
nism still remaining to be discovered.
Methods
Cell lines and patients
A panel of 10 tumours from primary NBs (4 Stage 2, all
from patients with no evidence of decease at last follow-
up, and 6 Stage 3 or 4 tumours, all from patients with
Methylation status of APITD1Figure 2
Methylation status of APITD1. Black boxes indicate methylation, white boxes no methylation, position relative to start 
codon is indicated at the top.
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SK-N-BE (2), SK-N-SH, SK-N-DZ, SK-N-F1 and SH-SY-5Y)
were analyzed (Table 1).
Expression analysis
cDNA preparation
Total RNA was extracted from frozen (-70°C) NB tumour
tissue using RNeasy RNA extraction kit (Qiagen, Hilden,
Germany). 2.4 µg total-RNA of each sample was reversed
transcribed to cDNA using Superscript II (Amersham,
Buckinghamshire, UK) and random hexamer primers, all
according to supplier's protocol. All cDNAs were quality
tested by amplification of the housekeeping genes UNPH
and GAPDH.
Real time PCR -Endogenous control
To select the most appropriate endogenous control for the
real-time PCR quantification analysis, we tested eight dif-
ferent primary NB samples of different stages for their
expression levels of ten commonly used housekeeping
genes with TaqMan Human Endogenous Control Plate,
(Applied Biosystems, Foster City, CA). Analysis was per-
formed according to supplier's protocol. GUSB (β-glu-
curonidase) and B2M (β2-microglobulin) showed least
variations in ∆CT levels, and were expressed at constant
levels in all samples regardless of NB-stage. GUSB was
selected, and further used as an internal reference for
normalization in the real-time PCR quantification analy-
sis (Abel et al., submitted).
Real time PCR- TaqMan
TaqMan primers and probes were derived from the com-
mercially available "TaqMan® Assays-on-Demand™ Gene
Expression Products" (URL:http://myscience.appliedbio
systems.com). Real-time PCR was performed in 384-well
plates using ABI PRISM® 7900HT Sequence Detection
Organization of the 5' region of APITD1Figure 3
Organization of the 5' region of APITD1. The CpG island, predicted promoter and analyzed region including the region 
of partial methylation are indicated.
Table 1: Clinical data for the primary tumours used in this study.
Patients/cell lines NB stage 1p-del Ploidi Outcome
18F8 2A neg NED
20S9 2 neg NED
23S4 2 neg 3n NED
25S9 2 neg NED
4F1 4 neg DOD
10S2A 4 pos DOD
13S0 4 pos DOD
13S1 3 pos DOD
15S3 4 neg/pos DOD
17S2 4 neg DOD
Column 3: 1p-del, 1p-deletion; neg, negative; pos, positive; neg/pos; ambiguous results based on microsatellite marker analysis (according to 
Martinsson et al. [6]) and FISH. Column 5: NED, no evidence of disease; DOD, dead of disease.
Partial
methylation of 
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µl) were carried out in duplicate with 0.1 µl template
cDNA according to manufacturers protocol (Applied Bio-
systems). In each assay, a standard curve with six cDNA
dilutions was recorded and two non-template controls
were included.
Quantification was performed by the standard-curve
method. The mean CT-value for duplicates were calcu-
lated, and the gene concentration (or gene copy numbers)
of test samples was interpolated based on standard curves.
All samples were normalized by dividing the concentra-
tion of the test gene with the concentration of the house-
keeping gene β-glucuronidase (GUSB) in the same cDNA
sample.
The logarithms of the expression levels were compared
with Student's two-sided t-test on each group of tumours;
low stage and high stage tumours.
Methylation analysis
Bisulphite modification
DNA was phenol extracted with the use of phase lock gel
(Eppendorf AG, Hamburg, Germany) according to stand-
ard procedure and was, with some minor changes, modi-
fied according to previously published papers [24,33].
Briefly, 1 µg of genomic DNA was digested with restriction
Table 2: Putative promoter regions and CpG island predictions.
Gene Promoter region CpG island Amplified region
UBE4B -1212 to -492 -1157 to -150 -959 to -494
KIF1B -22392 to -21141 -22444 to -20935 -22517 to -21874
PGD -185 to +7 -680 to +728 -157 to +144
APITD1a -250 to +30 -389 to +643 -418 to +321
DFFA +65 to +264 -164 to +256 -266 to +142
PEX14 - -2806 to -2362 -2752 to -2481
a For APITD1, the methylation status was analyzed for three different fragments. Column 2: Putative promoter regions according to Genomatix 
Promoter Inspector software. No promoter region was detected in PEX14. Column 3: CpG island prediction by MethPrimer (for CpG island 
criteria, see materials and methods). Column 4: Region amplified with the primers used in this study.
Table 3: PCR primers for amplification; all primers are designed for the sense strand.
Gene Primer Sequence Length of fragment (bp) Accession number
UBE4B FP 5'-TTGTTAGTTTATTTGGTTTAGGTT-3' 466 NM_006048
RP 5'-TAACAAAACCCAACACTATAAAAAAAACCCCT-3'
KIF FP 5'-TTTTTAAGGGTATTTTTTAGAAGGG-3' 644 NM_015074
RP 5'-ACTATAACCAATCACAACACAAAACTC-3'
PGD FP-A 5'-GTGAGTTGTTATGGTTATAGTTG-3' 301 NM_002631
FP-B 5'-ATGGTGTGGTTTTATGGTTTTATTT-3'
RP 5'-CAAAATCACAAAACCCCAAATAA-3'









DFFA FP 5'-AAGTTAAAAATAATTTTTAGGTTGAAT-3' 407 NM_004401
RP 5'-ACCAACCCTTACTCCTCAAATCT-3'
PEX14 FP 5'-TGATTAGTTAGGTTTTAGAAAGATGG-3' 333 NM_004565
RP 5'-CAAATAAAACCAAAAATACTAACAAAC-3'
Column 2: FP, forward primer; RP, reverse primer; FP-A and FP-B, primers used for semi-nested PCR together with the same reverse primer. 
Column 5: UCSC Genome Browser August 2001 draft sequence was used as reference sequence (URL: http://genome.ucsc.edu).Page 7 of 9
(page number not for citation purposes)
Molecular Cancer 2005, 4:10 http://www.molecular-cancer.com/content/4/1/10endonucleases that cut close but outside the region of
interest. The DNA was then denaturated in 0.3 M freshly
prepared NaOH at 40°C for 15 minutes. Sodium metabi-
sulphite (Sigma-Aldrich CO, St Louis, MO) and urea, at a
final concentration of 1.73 M and 5.36 M respectively,
were added in order to sulphonate the unmethylated
cytosines, along with hydroquinone (0.5 mM).
Conversion was carried out at 55°C for 16 hours, with a
temperature rise to 95°C for 30 seconds every third hour.
DNA was purified with Wizard DNA clean up system
(Promega Corporation, Madison, WI) according to the
manufactures instructions and desulphonated in 0.3 M
NaOH at 37°C for 15 minutes. DNA was then precipi-
tated in ethanol, resuspended in distilled H2O and stored
at -20°C.
Promoter analysis and DNA amplification
The putative promoter regions of the genes were predicted
using Genomatix Promoter Inspector software (URL:
http://www.genomatix.de) and CpG islands with Meth-
Primer software (URL: http://www.urogene.org/meth
primer/; Table 2) [34]. These regions, or parts of them,
were amplified with one primer pair, or if needed, with
semi-nested primers (Table 3). The methylation status
was analyzed using bisulphite sequencing. Conditions for
PCR amplification were 1× PCR Gold Buffer (Applied Bio-
systems), 0.5 mM dNTPs, 2.0–3.0 mM MgCl2, 0.4 µM of
forward and reverse primers respectively and 1 unit of
AmpliTaq Gold, in a total volume of 50 µl. Reactions were
denatured at 95°C for 10 min followed by 5 cycles of
95°C for 1 min, 49–55°C for 2 min, 72°C for 3 min and
30 cycles of 95°C for 30 sec, 49–55°C for 2 min, 72°C for
1 min 30 sec and ending with 10 min extension at 72°C.
The PCR products were immediately sequenced or cloned
into a sequencing vector using the TOPO T/A cloning kit
(Life Technologies Invitrogen, Carlsbad, CA), where after
10–30 clones were picked. PCR products were purified
with ExoSAP-IT™ (USB Corporation, Cleveland, Ohio)
and sequencing was carried out using forward or reverse
primer with ABI Prism BigDye™ cycle sequencing Ready
Reaction Kit (Applied Biosystems). The samples were ana-
lyzed in an ABI 3100 or an ABI 3730 Genetic Analyzer.
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